Ubrelvy (Ubrogepant)

Ubrogepant is a medicine used to treat a migraine once it starts. It is a pill you swallow. It works by blocking a protein called CGRP that plays a big part in migraine pain.

Brand names:Ubrelvy
Medication

What people taking Ubrelvy (Ubrogepant) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ubrelvy (Ubrogepant) for Migraines?

NameHow it went

About Ubrelvy (Ubrogepant)

What It's For

Ubrogepant, sold as Ubrelvy, is a prescription tablet that adults take to treat a migraine attack once it has started, whether or not the attack comes with aura (visual or other warning symptoms before the headache). It is meant to stop the attack in progress. It does not prevent migraines or reduce how often they happen, so people who need fewer attacks use a separate preventive treatment. Ubrogepant belongs to a newer group of migraine medicines called gepants. Triptans, such as sumatriptan, remain the usual first choice for treating attacks, but they do not work well for everyone and some people cannot tolerate them. Ubrogepant gives those people another option. It is not approved for children or teenagers.

How It Works

During a migraine, nerves around the head release a messenger called calcitonin gene-related peptide, or CGRP. CGRP widens blood vessels around the brain and is thought to drive inflammation in the membranes that cover it, which appears to feed the throbbing pain and sensitivity of an attack. Ubrogepant blocks the receptor that CGRP acts on, so the messenger has less effect and the attack can settle. Unlike triptans, gepants do not cause widespread narrowing of blood vessels. That matters because triptans are not used in people with certain heart or circulation problems, such as coronary artery disease or a past stroke. Blocking CGRP explains much of how ubrogepant works, but it does not help every person or every attack.

Dosage & Administration

Ubrelvy comes as 50 mg and 100 mg tablets, taken by mouth with or without food when a migraine starts. If the headache is still there or comes back, a second dose can be taken at least 2 hours after the first. The total should not exceed 200 mg in 24 hours. The safety of treating more than 8 migraines in a 30-day period has not been established, so frequent use is a reason to talk with the prescriber about prevention. Some situations call for a 50 mg dose (and for some medicines, no second dose that day), including severe liver or kidney disease and use with certain other medicines. People with end-stage kidney disease should not take it. The prescriber will choose the strength that fits the person's other medicines and health.

Side Effects

Most people take ubrogepant without notable side effects. The most common are nausea and sleepiness or tiredness, and some people notice a dry mouth. Ubrogepant and related medicines can raise blood pressure or make existing high blood pressure worse, most often within the first week of use. People who check their blood pressure at home and see readings noticeably higher than usual should let the prescriber know. It can also bring on or worsen Raynaud's phenomenon, in which the fingers or toes turn cold, numb, white or blue because their blood vessels narrow. If this happens, stop ubrogepant and contact the prescriber. Serious allergic reactions are uncommon and can appear minutes to days after a dose. Trouble breathing or swelling of the face or throat needs emergency medical care right away, and the medicine should not be taken again.

Interactions & Warnings

Ubrogepant is broken down in the liver by an enzyme called CYP3A4, so medicines that block or speed up that enzyme change how much reaches the bloodstream. It must not be taken with strong blockers, such as the antifungals ketoconazole and itraconazole or the antibiotic clarithromycin, because levels can rise sharply. Moderate blockers include grapefruit juice, the antifungal fluconazole, the antibiotic ciprofloxacin and the blood pressure medicine verapamil. With any of these, the dose is 50 mg and no second dose should be taken within 24 hours. Strong enzyme boosters, such as the seizure medicine phenytoin, barbiturates, the antibiotic rifampin and the herbal supplement St. John's wort, should be avoided because ubrogepant is likely to stop working. Tell the prescriber and pharmacist about every prescription, over-the-counter medicine, supplement and regular grapefruit habit. People with high blood pressure or a history of Raynaud's phenomenon should discuss these risks before starting. There is little information about ubrogepant in pregnancy, so anyone pregnant or planning a pregnancy should review options with the prescriber. Small amounts pass into breast milk, and the effect on a nursing infant is not known.

What to Expect

In clinical trials, about one in five people who took ubrogepant for a moderate to severe migraine were completely pain free two hours later, compared with roughly one in eight who took a placebo. About six in ten had their pain eased to mild or none at two hours, compared with about half on placebo. About four in ten no longer had their most bothersome symptom, such as light sensitivity, sound sensitivity or nausea, at two hours, compared with under three in ten on placebo. Results vary from attack to attack, so it often takes a few migraines to judge whether it helps. Keeping a simple record of when each dose was taken and how the attack went makes that review easier. If ubrogepant is needed often, or attacks are becoming more frequent, a preventive plan is usually the next conversation.

Questions to Ask Your Doctor

  1. 1.Is ubrogepant a better fit for me than a triptan, given my health and past experience with migraine medicines?
  2. 2.Which strength should I take, and when should I take a second dose?
  3. 3.Do any of my current medicines, supplements or grapefruit habits change how I should take it?
  4. 4.Should I check my blood pressure after starting, and what readings should prompt a call?
  5. 5.If I am treating several migraines a month, should we also start a preventive treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.